Bessemer Group’s ImmunityBio IBRX Stock Holding History

Bessemer Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-50	Closed	–	–	2512
2025 Q1	$0	Hold	50	–	–	﹤0.01%	2585
2024 Q4	$0	Hold	50	–	–	﹤0.01%	2551
2024 Q3	$0	Hold	50	–	–	﹤0.01%	2642
2024 Q2	$0	Buy	+50	New	+$330	﹤0.01%	2080

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Bessemer Group's IBRX Position: Q2 2025 in Review

Bessemer Group sold out of ImmunityBio (IBRX) in Q2 2025, closing a stake of 50 shares.

Bessemer Group first reported a position in IBRX in Q2 2024 and held it in 4 quarters. The position peaked at $0 in Q1 2025. 241 funds tracked by Wall St. Rank hold IBRX as of Q2 2025.

Bessemer Group reported no remaining ImmunityBio position as of Q2 2025 after selling out during the quarter.
Bessemer Group sold 50 ImmunityBio shares in Q2 2025.
Bessemer Group first reported a position in ImmunityBio in Q2 2024 and held it in 4 quarters.
Bessemer Group's ImmunityBio position peaked at $0 in Q1 2025.
241 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2025.

Based on Bessemer Group's 13F filing for Q2 2025, filed 1 Aug 2025.